Literature DB >> 2515064

Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man.

O Vesterqvist1, K Gréen.   

Abstract

The effect of a single oral dose of 500 mg naproxen on the synthesis in vivo of thromboxane A2 and prostacyclin was studied in healthy volunteers. The synthesis of the prostanoids was assessed by measuring the urinary excretion of the metabolites 2,3-dinor-TxB2 and 2,3-dinor-6-keto-PGF1 alpha, respectively, using stable isotope dilution assays based on gas chromatography - mass spectrometry. Naproxen caused significant inhibition of the excretion of both metabolites for about two days. The reduction of the thromboxane metabolite was more pronounced (75% inhibition) than that of the prostacyclin metabolite (about 50% inhibition). The data support the idea that naproxen causes reversible inhibition of cyclooxygenase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515064     DOI: 10.1007/bf00562545

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Pharmacokinetics of high-dosage naproxen in elderly patients.

Authors:  F A Van den Ouweland; P A Jansen; Y Tan; L B Van de Putte; C A Van Ginneken; F W Gribnau
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1988-03

2.  In vivo synthesis of thromboxane and prostacyclin in man in health and disease. Data from GC-MS measurements of major urinary metabolites.

Authors:  K Gréen; O Vesterqvist
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1986

Review 3.  Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs.

Authors:  G G Graham
Journal:  Med J Aust       Date:  1987 Dec 7-21       Impact factor: 7.738

Review 4.  Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans.

Authors:  O Vesterqvist
Journal:  Scand J Clin Lab Invest       Date:  1988-09       Impact factor: 1.713

5.  The chemical structure of prostaglandin X (prostacyclin).

Authors:  N Whittaker; S Bunting; J Salmon; S Moncada; J R Vane; R A Johnson; D R Morton; J H Kinner; R R Gorman; J C McGuire; F F Sun
Journal:  Prostaglandins       Date:  1976-12

Review 6.  Non-steroidal anti-inflammatory analgesics other than salicylates.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans.

Authors:  O Vesterqvist; K Gréen; F H Lincoln; O K Sebek
Journal:  Thromb Res       Date:  1984-01-01       Impact factor: 3.944

8.  Development of a GC-MS method for quantitation of 2,3-dinor-6-keto-PGF1 alpha and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs.

Authors:  O Vesterqvist; K Gréen
Journal:  Prostaglandins       Date:  1984-07

9.  Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans.

Authors:  S Cronberg; E Wallmark; I Söderberg
Journal:  Scand J Haematol       Date:  1984-08

10.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more
  2 in total

Review 1.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 2.  NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species.

Authors:  Rajeshwary Ghosh; Azra Alajbegovic; Aldrin V Gomes
Journal:  Oxid Med Cell Longev       Date:  2015-09-20       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.